Evinacumab (REGN1500) is a human monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3) and belongs to the IgG4 subclass. This antibody effectively reduces plasma lipid levels by inhibiting the activity of ANGPTL3. It has demonstrated efficacy in preclinical models, specifically in dyslipidemic mice, showcasing its potential in lipid metabolism regulation. Evinacumab is applicable for research in various lipid disorders, including homozygous familial hypercholesterolemia (HoFH), refractory hypercholesterolemia (both familial and non-familial), and severe hypertriglyceridemia, providing a valuable tool for studies in lipid regulation and cardiovascular disease.
Evinacumab (REGN1500) is a human monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3) and belongs to the IgG4 subclass. This antibody effectively reduces plasma lipid levels by inhibiting the activity of ANGPTL3. It has demonstrated efficacy in preclinical models, specifically in dyslipidemic mice, showcasing its potential in lipid metabolism regulation. Evinacumab is applicable for research in various lipid disorders, including homozygous familial hypercholesterolemia (HoFH), refractory hypercholesterolemia (both familial and non-familial), and severe hypertriglyceridemia, providing a valuable tool for studies in lipid regulation and cardiovascular disease.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
